Evidence-based guideline for recognition, grading, and management of immune-related adverse events (irAEs) across all organ systems in patients receiving checkpoint inhibitor immunotherapy.
A comprehensive, evidence-based clinical guideline for the recognition, grading, and management of immune-related adverse events (irAEs) in adult patients receiving immune checkpoint inhibitor (ICI) therapy. This resource synthesizes recommendations from major international oncology and immunotherapy professional societies to provide a single integrated reference for medical oncologists, hematologists, hospitalists, emergency medicine physicians, subspecialty consultants, advanced practice providers, oncology pharmacists, and oncology nurses who care for patients receiving or who have recently received checkpoint inhibitor immunotherapy.1 2 3 4 5
Immune checkpoint inhibitors have transformed the treatment landscape across a broad range of malignancies. By releasing inhibitory brakes on T-cell-mediated antitumor immunity, these agents produce durable responses in cancers that were previously refractory to systemic therapy. However, the same mechanism that drives antitumor efficacy also produces a distinctive spectrum of immune-related adverse events that can affect virtually any organ system. These toxicities differ fundamentally from the adverse effects of cytotoxic chemotherapy in their mechanism, timing, clinical presentation, and management. Whereas chemotherapy toxicities typically correlate with the nadir of myelosuppression and resolve with count recovery, irAEs are autoimmune or autoinflammatory in nature, can present at any time during or after treatment, and require immunosuppressive rather than supportive management strategies.
The overall incidence of irAEs ranges from approximately 60% to 85% with anti-CTLA-4 monotherapy, 55% to 70% with anti-PD-1/PD-L1 monotherapy, and 80% to 95% with combination anti-CTLA-4 plus anti-PD-1 therapy. Grade 3 or higher irAEs occur in approximately 20% to 30% of patients on anti-CTLA-4 monotherapy, 10% to 15% on anti-PD-1/PD-L1 monotherapy, and 40% to 60% on combination regimens.1 6 While the majority of irAEs are mild to moderate in severity and manageable with corticosteroids, certain toxicities – including myocarditis, severe pneumonitis, severe colitis, and neurologic emergencies – carry significant mortality risk and demand urgent recognition and aggressive management.
Early recognition, systematic grading, and protocol-driven management are the cornerstones of safe immunotherapy administration. This guideline provides detailed, grade-based management algorithms for each organ system, specific corticosteroid dosing and tapering schedules, immunosuppressive escalation protocols, criteria for immunotherapy rechallenge, and guidance on special populations.
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Overview of Checkpoint Inhibitors and General Principles of irAE Management | Classes of immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4, LAG-3); mechanism of irAE development; general incidence and timing; CTCAE grading overview; general principles for holding and discontinuing therapy; corticosteroid dosing protocols and taper schedules; immunosuppressive escalation (infliximab, mycophenolate, tacrolimus, anti-thymocyte globulin); infusion reactions vs irAEs |
| Part 2 | Dermatologic, Gastrointestinal, and Hepatic irAEs | Dermatologic: maculopapular rash, pruritus, bullous pemphigoid, lichenoid reactions, vitiligo, Stevens-Johnson syndrome/toxic epidermal necrolysis; Gastrointestinal: immune-mediated colitis and diarrhea (differential diagnosis including C. difficile, CMV colitis), grade-based management, infliximab/vedolizumab escalation; Hepatic: immune-mediated hepatitis, grading, differential diagnosis, mycophenolate escalation |
| Part 3 | Endocrine and Pulmonary irAEs | Thyroid disorders (thyroiditis, hypothyroidism, hyperthyroidism); adrenal insufficiency (primary and secondary); hypophysitis; type 1 diabetes mellitus; Pulmonary: pneumonitis grading, imaging patterns, bronchoalveolar lavage, differential diagnosis, grade-based management including high-dose corticosteroids and immunosuppressive escalation |
| Part 4 | Cardiac, Neurologic, Renal, and Musculoskeletal irAEs | Myocarditis (high mortality, urgent management protocol); pericarditis; arrhythmias; Neurologic: peripheral neuropathy, myasthenia gravis, encephalitis, Guillain-Barre syndrome, aseptic meningitis, transverse myelitis; Renal: acute interstitial nephritis, glomerulonephritis; Musculoskeletal: inflammatory arthritis, myositis, polymyalgia-like syndrome |
| Part 5 | Hematologic, Ophthalmologic irAEs, Special Populations, and Rechallenge | Immune thrombocytopenia, autoimmune hemolytic anemia, aplastic anemia, acquired hemophilia; Ophthalmologic: uveitis, episcleritis, orbital inflammation; Combination immunotherapy toxicity profiles; Rechallenge criteria and monitoring; Preexisting autoimmune disease; irAEs in special populations (elderly, organ transplant recipients); Multidisciplinary consultation triggers; Patient education and monitoring |
Scope and Applicability: This guideline applies to all healthcare professionals involved in prescribing, administering, and monitoring immune checkpoint inhibitor therapy in adult oncology patients, as well as consultants from any subspecialty who may be asked to evaluate suspected irAEs. This includes medical oncologists, hematologists, hospitalists, internists, emergency medicine physicians, pulmonologists, cardiologists, neurologists, gastroenterologists, endocrinologists, dermatologists, rheumatologists, nephrologists, ophthalmologists, oncology nurse practitioners, physician assistants, clinical pharmacists, and oncology nurses across all care settings.
Limitations: No guideline can anticipate all clinical scenarios. This document is not intended to replace individual clinical judgment by qualified professionals. Local institutional protocols, patient-specific factors (including tumor type, performance status, comorbidities, concurrent medications, and prior irAE history), and emerging evidence must always be considered in clinical decision-making. Management of irAEs frequently requires multidisciplinary collaboration, and early subspecialty consultation is encouraged for complex or severe presentations.
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology (ASCO) clinical practice guideline update. J Clin Oncol. 2021;39(36):4073-4126. ↩︎ ↩︎
Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: European Society for Medical Oncology (ESMO) clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217-1238. ↩︎
National Comprehensive Cancer Network (NCCN). Management of immunotherapy-related toxicities. NCCN Clinical Practice Guidelines in Oncology. Version 1.2025. ↩︎
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. ↩︎
Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(4):387-405. ↩︎
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. ↩︎
Management of immune-mediated hematologic toxicities, ophthalmologic irAEs, combination immunotherapy toxicity profiles, rechallenge criteria, preexisting autoimmune disease, special populations, multidisciplinary triggers, and patient education.
Grade-based management of immune-mediated myocarditis, pericarditis, neurologic toxicities (myasthenia gravis, encephalitis, Guillain-Barre, neuropathy), nephritis, inflammatory arthritis, and myositis.
Grade-based management of immune-mediated endocrine toxicities (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes) and pneumonitis including workup, corticosteroid protocols, hormone replacement, and immunosuppressive escalation.
Grade-based management of immune-mediated dermatologic toxicities (rash, pruritus, bullous pemphigoid, SJS/TEN), colitis/diarrhea, and hepatitis including workup, corticosteroid protocols, and immunosuppressive escalation.
Classes of immune checkpoint inhibitors, mechanism and epidemiology of irAEs, CTCAE grading, general management framework, corticosteroid protocols, immunosuppressive escalation, and infusion reactions.